All posts by imreal

Romacorp, Inc. Announces New Talent to Executive Team to Oversee the Brand’s Global Collection of Casual Dining Concepts


News Image

Having worked with Romacorp for the past eight years and counting, I’m dedicated to the growth and success of the brand, its talented team and worldwide customers, and I look forward to taking on this new leadership role.

Romacorp, Inc., the parent company of Tony Roma’s®, proudly appoints new talent and executives to its leadership team, including the promotion of brand-veteran, John Brisco, to president & CEO. This announcement sets the foundation for the next phase of growth for Romacorp, as it looks to expand its restaurant portfolio and dining offerings.

Romacorp is best known for its globally-recognized restaurant brand, Tony Roma’s, which is a full-service, family-friendly dining destination that serves World-Famous Baby Back Ribs and beloved menu classics, such as premier burgers, steaks and seafood. This year, Romacorp plans to unveil a new concept that is fast-casual, providing the same quality ingredients and fresh preparations in an authentic quick-service space for guests on-the-go.

“Having worked with Romacorp for the past eight years and counting, I’m dedicated to the growth and success of the brand, its talented team and worldwide customers, and I look forward to taking on this new leadership role,” said John Brisco, new president & CEO of Romacorp. “Romacorp will continue to build its leadership capacity and has plans for unveiling new and exciting dining experiences for customers this year.”

Today, Romacorp announces its leadership team, including the following recent appointments and internal promotions:

John Brisco – President & CEO / Board of Directors

Formerly the President of Global Franchise for Romacorp, Brisco has recently been promoted to president & CEO and is one of two new board members for the company. John is an industry veteran with more than 35 years of experience in the hospitality and restaurant realm, previously serving as president of international development for Ruby Tuesday, president of international franchise for Sbarro’s, and vice president of international development for TGI Fridays.

Alan Rosen – Board of Directors

Rosen joins Romacorp’s new board members team with more than three generations worth of knowledge in the restaurant industry. Graduating from Cornell University’s School of Hotel Administration, Alan has grown his profile from director of marketing for Junior’s Restaurants and Bakery to becoming a co-owner of the company, alongside his brother. Alan has helped grow a small, local Brooklyn bakery into an internationally renowned bakery, selling world-famous cheesecake.

Dan Cronk – Executive Vice President, Legal Administration

Cronk was named executive vice president, legal & administration, as of November 2019, and was recently appointed as a director of Roma Systems, Inc. and Roma Franchise Corporation in January 2020. Cronk has worked with the Romacorp brand since 2016, serving in various positions including special counsel, general counsel and secretary. He also engages in the private practice of law (Law Offices of Daniel T. Cronk, PLLC) in Lucas, Texas.

Ramon Bourgeois – Senior Vice President, Global Franchise

Bourgeois is a restaurant industry veteran with more than 25 years of industry experience. Recently, he was named senior vice president, global franchise of Roma Franchise Corporation, Romacorp, Inc. and Roma Systems, Inc. as of November 2019, and was appointed a director of Roma Systems, Inc. and Roma Franchise Corporation in January 2020. Having worked for Romacorp for five years, Bourgeois has also held previous titles such as vice president and regional vice president for the brand. Prior to that, Bourgeois was the director of operations for areas USA.

Darren Gino – Vice President, Information Technology & Marketing

Gino was appointed vice president, information technology & marketing of Romacorp, Inc., Roma Franchise Corporation and Roma Systems, Inc. as of December 2019. Before that, Mr. Gino was the director of information technology for Romacorp from January 2016 until November 2019. Before working with Romacorp, Gino was a project leader and project manager for Darden Restaurants for more than nine years.

Nina Bishop – Vice President, Accounting & Human Resources

Bishop was appointed vice president, accounting & human resources of Romacorp, Inc., Roma Franchise Corporation and Roma Systems, Inc. as of December 2019. Before that, she was the director of accounting for Romacorp for three years. Previously, Ms. Bishop was the controller for NMA Accounting LLC from September 2008 until August 2016.

About Romacorp, Inc.

Romacorp, Inc., is the parent company of Tony Roma’s restaurants, the world’s largest casual dining concept specializing in ribs. Headquartered in Orlando, Florida, Romacorp, Inc. has more than 135 restaurant locations in more than 25 countries and is one of the most globally recognizable names in the industry. The first Tony Roma’s restaurant opened 46 years ago in North Miami, Florida. For more information about Romacorp, Inc. and Tony Roma’s, visit http://www.tonyromas.com.

Share article on social media or email:

Rimidi Unveils New App to Accelerate Patient Screenings for COVID-19


News Image

“With the app, we can help keep potentially infectious individuals from exposing other patients or staff in the healthcare system in waiting rooms, emergency rooms, or triage before they are identified and separated.”

Rimidi, a cloud-based software platform, today announced the launch of its patient-reported outcomes survey app to help limit the spread of COVID-19 in healthcare settings. Currently, the app is in expedited beta testing by select U.S. health systems operating in the regions at the greatest risk of Coronavirus outbreak. Rimidi anticipates general availability of the app before the end of March 2020.

“One of the greatest challenges in China and across other countries that faced early COVID-19 outbreaks has been hospital-based transmission,” said Lucienne Ide, MD, PhD, founder of Rimidi. “With the app, we can help keep potentially infectious individuals from exposing other patients or staff in the healthcare system in waiting rooms, emergency rooms, or triage before they are identified and separated.”

Combatting Coronavirus Spread via Advanced EHR-integrated Technology

Along with their text message appointment reminder, patients are sent a brief COVID-19 screening survey inquiring about current symptoms and recent travel. Integrated within the electronic health record (EHR), patient responses are easily captured and analyzed by clinical teams. The survey respondents demonstrating potential risk of COVID-19 exposure, in accordance with the latest CDC guidelines, are immediately notified with the appropriate next steps of care and treatment options, while the healthcare system is confidentially made aware of the at-risk patient.

Ultimately, the simplicity and accessibility of Rimidi’s screening app will help minimize the spread and impact of COVID-19 in healthcare settings by reducing the number of undiagnosed patients interacting with patients seeking standard care. It will also limit exposure of healthcare staff to potentially infectious patients in settings that are not adequately prepared.

Dr. Ide added, “The need for such a screening app was advocated for in a JAMA article following the Ebola outbreak in 2014. Today, the potential COVID-19 public health emergency reinforces the healthcare industry’s need for interoperability and stronger data-sharing rules to ease the flow of information, which enables rapid deployment of a single application across multiple EHR platforms.”

Rimidi remains in close coordination with the Centers for Disease Control and Prevention and will incorporate new evidence and its evolving guidance into the screening app as it emerges. This may include ongoing remote monitoring and self-reporting by patients in quarantine, among other features.

For more information and to be notified when the app is widely available for healthcare systems, please visit rimidi.com/covid19.

About Rimidi

Rimidi is a cloud-based software platform that enables personalized management of health conditions across populations. Created by doctors, Rimidi avoids the disconnect in connected care by combining patient-generated health data with clinical data from the EHR to drive patient-specific clinical insights and actions. The net effect is a better health system with optimized clinical workflows that enable better decisions, better relationships, better outcomes and ultimately a better healthcare system. For more information, visit rimidi.com and follow us on Facebook, Twitter and LinkedIn.

Media Contact:

Cortney Williams

ARPR, on behalf of Rimidi

cortney@arpr.com

855.300.8209

Share article on social media or email:



LabRoots Announces Neuroscience 2020 Virtual Conference to Promote Research Worldwide and The NIH BRAIN Initiative


News Image

LabRoots, the leading scientific social networking website offering premier, interactive virtual events and webinars, will be hosting approximately 15,000 neuroscience researchers, clinicians, and scientists from around the globe who are dedicated to understanding the brain and nervous system. The annual, free Neuroscience Virtual Event will capture emerging developments in Neuroscience and the impact brain research has on society, together with the latest innovations.

With nearly 70 speakers, including two stellar keynote deliveries, 15 on-demand discussions, and 13 panels, Neuroscience 2020 showcases an extremely comprehensive program supported by the organizing committee of renowned academia and industry experts, The NIH BRAIN team, and dedicated sponsors.

Featuring neural circuit and behavior dynamics, cell diversity, tool and technology development, advancing human neuroscience: basic to clinical projects, and neuroethics presented by early career scientists diverse in background, The NIH BRAIN Initiative session will preview “a multidisciplinary approach to neuroscience.” The agenda also highlights the scourge of neurodegenerative diseases and dementia, and behavioral and psychiatric disorders to expand on the all-encompassing theme of the conference – brain function in health and disease.

This year’s agenda commences with a keynote academia speaker, Dario Alessi, FRS FMedSci FRSE, Director, Professor of Signal Transduction at University of Dundee, describing the nuts and bolts of the LRRK2 signaling pathway and how it is linked to Parkinson’s Disease, and new approaches that could be exploited to better diagnose the disease. Following, Dr. Walter Koroshetz, Director of the National Institute of Neurological Disorders and Stroke who played a significant role in the revolution in acute stroke care in the US and the growth of the neurointensive care field, will deliver a keynote presentation on The BRAIN Initiative and its promise for new Neurotechnologies to more effectively diagnose and treat neuro/mental/substance abuse disorders.

The featured notable speakers cover many significant areas of Neuroscience including open science and data sharing for behavioral neuroscience, understanding the pitfalls and advantages of cognitive testing in mouse models of disease, deciphering the spreading of neuropathologies in neuronal circuits using a high capacity microfluidics platform, and learning about a protein that is a potential key player in neurodegeneration and aging, and much more.

“This year’s Brain Initiative track will showcase the power of combining diverse expertise and teamwork in tackling some of the most challenging areas of contemporary neuroscience research,” commented Karen K. David, Ph.D., Program Director, BRAIN Initiative. “We are excited to feature through LabRoots the breadth of expertise of our early-career scientists and representative collaborative projects that tackle the circuit basis of behavior, cell diversity, resource development, and human neuroscience. Through Labroots’ virtual environment, we are able to feature the team neuroscience approach that can often be difficult to showcase through usual channels including conferences.”

“Progressing at a remarkable pace, Neuroscience is one of the most exciting fields of biomedical research and our interactive forum continues to lead our mission in sharing cutting-edge science on a global front,” said Greg Cruikshank, Chief Executive Officer of LabRoots. “We look forward to deepening the knowledge through valuable discussions, as the research of the human brain continues to evolve.”

Produced on LabRoots’ robust platform, this online environment with exhibit and poster halls, and networking lounge allows attendees to connect seamlessly across all desktop and mobile devices. By participating in this event, Continuing Education credit (1 per presentation) can be earned for a maximum of 40 credits.

For more information or to register for the event, click here. Participants can follow the conversation online by using #LRneuro.

About LabRoots

LabRoots is the leading scientific social networking website, and primary source for scientific trending news and premier educational virtual events and webinars and more. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, LabRoots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events.

Share article on social media or email:

Ephesoft CEO and CFO Selected to Present to Innovators and Investors at The Montgomery Summit


A global community of investors and leaders

The Montgomery Summit 2020

“Ephesoft has seen tremendous global growth in its first 10 years, and we are poised to grow our recurring revenues by more than 75% this year, as we set our sights on a new approach to the content capture industry called Context Driven Productivity.” — Ike Kavas, founder and CEO at Ephesoft

Ephesoft, Inc., a leader in content acquisition and data enrichment solutions, today announced that its founder and chief executive officer, Ike Kavas, and Naren Goel, chief financial officer, will present as an Emerging Company at The Montgomery Summit, March 4-5 in Santa Monica, Calif. Kavas was selected to present Ephesoft’s data enrichment and workforce productivity vision, while Goel will speak as a panelist during The Montgomery Summit, which gathers entrepreneurs, investors and leading executives to discover the most important innovations in business and technology.

Kavas, who founded Ephesoft in 2010 with a vision to modernize and disrupt the content capture space with intelligent technology and scalable business models, is one of 140 CEOs selected to present his company vision from a pool of over 4,000 fast-growing organizations. Companies are evaluated based on their sector, growth stage, metrics — including size, expansion and industry engagement — as well as their overall story and vision. Kavas will share his roadmap for Ephesoft in 2020 and beyond, including the company’s new discipline, Context Driven Productivity, during his 11:00 AM presentation on Thursday, March 5 in Wilshire III at the Fairmont Miramar Hotel and Bungalows.

“Ephesoft has seen tremendous global growth in its first 10 years, and we are poised to grow our recurring revenues by more than 75% this year, as we set our sights on a new approach to the content capture industry called Context Driven Productivity,” said Kavas. “We are revolutionizing digital transformation projects to bring true autonomy to organizations by transforming flat data into semantic data — creating context and relationships to disparate data points.” Kavas will focus his presentation on Ephesoft’s mission, vision, growth, market dynamic, executive team and strategy for explosive success. “We are looking for the right investors to join our productivity revolution, helping companies turn their massive troves of enterprise data into empowering assets that lift the entire organization and ultimately fuel a next-generation workforce,” Kavas added.

Goel, Ephesoft CFO since early 2018, will speak on a panel titled “How to Secure Funding,” presented by Moss Adams at 9:30-10:30 AM on Wednesday, March 4 in Jones Library at the Fairmont Miramar. The panel will explore insights and analyses from venture capitalists, private equity experts and C-Suite visionaries as they discuss best practices for technology companies aiming to raise funding rounds and prepare for exits.

In addition to launching Context Driven Productivity as a new technology discipline in February, Ephesoft has claimed several industry honors in recent months, including CRN’s Top 100 Coolest Cloud Software and HousingWire’s Tech 100, as well as two top workplace honors in Orange County, Calif., where it is based. Kavas was an “Unstoppable” finalist in EY’s Entrepreneur of the Year award and was named best CEO of a small company by OCTANe. Goel was a CFO of the year finalist in Orange County.

Kavas is also scheduled to present at two other upcoming investor conferences. At the 32nd Annual ROTH Conference, March 15-17 at the Ritz Carlton in Laguna Niguel, Calif., Kavas will present Ephesoft’s history, vision and strategic plans. Kavas will also present at the JMP Securities Emerging Technology Conference in July 2020.

About Ephesoft

Ephesoft is the leader in Context Driven Productivity solutions, helping organizations maximize productivity and fuel their journey towards the autonomous enterprise through contextual content acquisition, process enrichment and amplifying the value of enterprise data. The Ephesoft Semantik Platform turns flat data into context-rich information to fuel data scientists, business users and customers with meaningful data to automate and amplify their business processes. Thousands of customers worldwide employ Ephesoft’s platform to accelerate nearly any process and drive high value from their content. Ephesoft is headquartered in Irvine, Calif., with regional offices throughout the US, EMEA and Asia Pacific. To learn more, visit ephesoft.com.

Kavas and Goel are also open to press and VC meetings and can be contacted at investorrelations@ephesoft.com or press@ephesoft.com.

Share article on social media or email:

Cell and Gene Therapies – Trends, Supply Chain Challenges and Solutions, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

The criticality and specialized handling needed for each shipment requires seamless execution of a vein-to-vein supply chain throughout the journey, and the manufacturers of these complex therapies must also consider the reliability, quality and cost effectiveness of any solution.

To control and direct the power of a patient’s immune system in order to fight disease is both ground-breaking as well as complicated. While the success of cell and gene therapy strives to become more mainstream and is increasingly the focus of researchers, the longer-term potential requires exploration. Researchers and manufacturers must translate the progress of cell and gene trials into broader programs targeting larger populations. Scalability and manufacturability are two challenges that the industry faces.

Nevertheless, before commercialization, cell and gene therapies encounter many other challenges as they progress towards their goal. The criticality and specialized handling needed for each shipment requires seamless execution of a vein-to-vein supply chain throughout the journey, and the manufacturers of these complex therapies must also consider the reliability, quality and cost effectiveness of any solution.

Join Darren Dasburg, Global Head of Cell Gene Services, Marken and Jeff Stone, Senior Director, Global Program Management, Marken in a live webinar on Thursday, March 19, 2020 at 9am EDT (1pm GMT).

For more information or to register for this event, visit Cell and Gene Therapies – Trends, Supply Chain Challenges and Solutions.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

ABOUT MARKEN

Marken is a wholly owned subsidiary of UPS. Marken is the only patient-centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. Marken maintains the leading position for Direct to Patient and Home Health care services, biological sample shipments and offers a state-of-the-art GMP-compliant depot network and logistic hubs in 51 locations worldwide for clinical trial material storage and distribution. Marken’s more than 1,000 staff members manage 85,000 drug and biological shipments every month at all temperature ranges in more than 150 countries. Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry. http://www.marken.com

To learn more about Xtalks, visit http://xtalks.com.

For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar/.

Share article on social media or email:

SAFE Health Selected as Finalist for 2020 SXSW PITCH


Cellphone screenshots of the SAFE App

The SAFE App

“Our goal is to empower young people to respect and protect their sexual health. We created a tool to have the conversation about sexual health between partners, while also providing access to easy and affordable testing…our mission is to end the spread and stigma of STDs in our lifetime.”

SAFE Health, a digital healthcare company focused on sexual health, has been selected as a finalist for the 12th annual SXSW Pitch® (formerly SXSW Accelerator) for its debut product, The SAFE App, which lets potential partners verify each others sexual health status and provides the easiest and least expensive way to get tested.

SXSW Pitch is the marquee event of South by Southwest® (SXSW®) Conference & Festivals (March 13 – 22, 2020) Startups Track, where leading startups from around the world showcase some of the most impressive technology innovations to a panel of hand-picked judges and a live audience. Out of the 937 companies that applied to present at SXSW Pitch 2020, SAFE was selected as one of 5 finalists in the Health, Wearables & Wellbeing category.

The event will be held the first weekend of SXSW Conference & Festivals on the fourth floor of the Downtown Hilton Austin, Salon D/E. The event will then culminate with the 2020 SXSW Pitch Awards Ceremony on Sunday evening, March 15, where winning startups from each category and a Best in Show winner will be announced and honored. SAFE and fellow finalists in the Health, Wearables & Wellbeing category will present on March 15th.

“Our goal is to empower young people to respect and protect their sexual health,”said Lauren Weiniger, co-founder of SAFE. “We created a tool to make it easier, and a little less awkward, to have the conversation about sexual health between partners, while also providing access to easy and affordable testing. It’s not about blame or shame, our mission is to end the spread and stigma of STDs in our lifetime.”

According to the CDC, STD rates have reached an all-time high in the U.S. for the fifth year in a row. Dating apps and social networks have played a significant role as they have expanded dating pools, enabling STIs to spread rapidly through diverse populations. The HIPAA-compliant SAFE App is the first real-world, practical solution to addressing what the CDC now calls a “public health crisis.” The app lets people import their medical records from any provider, so they can show their status on their phone (and confirm the status of their partners). The app also lets users schedule affordable testing at 30,000 locations across the country.

“For over a decade, SXSW Pitch has played a pivotal role in…giving promising companies the resources they need to succeed when it matters most and providing high profile exposure,” said SXSW Pitch Event Producer Chris Valentine. “Of the 503 companies who have participated since the competition’s inception, over 75 percent have gone on to secure funding and 16 percent have been acquired.”

For more information about SXSW Pitch and to view the complete list of finalists, visit: https://www.sxsw.com/pitch.

About SAFE App

SAFE App lets people show their verified STD status on their phone, and provides the easiest and least expensive way to get tested and treated. Users can import their medical records for free from any provider, or book testing at over 30,000 locations. SAFE has partnerships with many of the leading players in healthcare, including Quest, Labcorp, and Mayo Clinic. More than an app, SAFE is a movement to end the spread and stigma of STDs in our lifetime.

Download SAFE App here: http://www.safeapp.me

Photo assets can be found here: https://goo.gl/6zs47h

About SXSW

SXSW dedicates itself to helping creative people achieve their goals. Founded in 1987 in Austin, Texas, SXSW is best known for its conference and festivals that celebrate the convergence of the interactive, film, and music industries. An essential destination for global professionals, the event features sessions, showcases, screenings, exhibitions, and a variety of networking opportunities. SXSW proves that the most unexpected discoveries happen when diverse topics and people come together. SXSW 2020 will take place March 13 – 22, 2020. For more information, please visit sxsw.com.

Media Contact:

Bridget Garwood

The SAFE App

301-305-6284

Share article on social media or email:

Cytonus, the US-based Biotech Platform Company, gains a boost from Strategic Partnership with Europe-based Phoenestra


News Image

Cytonus is thrilled to gain the benefit of Phoenestra’s scientific excellence, quality IP assets, as well as the top talent of their highly experienced executives, who have decades of biopharma industry experience and were instrumental in the past development of more than eleven biologics that are n

With numerous products in its pipeline, Cytonus Therapeutics Inc. today announced a strategic partnership agreement with Phoenestra GmbH to accelerate Cytonus’ existing products and to expand the companies’ intellectual property assets. Cytonus is a biotech company founded in San Diego, California. Phoenestra is a biotech company located in Austria.

Phoenestra has developed IP assets in connection with cell reprogramming as well as non-invasive sources for cell lines. The strategic partnership with Cytonus will expand both companies’ combined IP assets through co-development collaboration projects. As part of the strategic partnership, Phoenestra will also provide Cytonus new manufacturing capabilities, including a new production facility focused on operating in full compliance with Good Manufacturing Practices (GMP). Since its inception, Phoenestra has focused on an end-to-end approach to ensure both quality control and scalability, starting with the efficient sourcing of material from unique cell sources and producing finished GMP-certified products.

“We are honored to join forces with Cytonus,” commented Phoenestra CEO and Founder Klaus Graumann, PhD. “Phoenestra will work to complement and accelerate Cytonus’ game-changing Cargocyte™ biotechnologies.”

“Our co-development projects will create fertile ground for further expanding the combined IP assets and pipeline of products for Cytonus and Phoenestra,” commented Phoenestra CFO and Founder Otto Kanzler.

“Cytonus is thrilled to gain the benefit of Phoenestra’s scientific excellence, quality IP assets, as well as the top talent of their highly experienced executives, who have decades of biopharma industry experience and were instrumental in the past development of more than eleven biologics that are now commercial products,” commented Cytonus’ Founder and CEO Remo Moomiaie-Qajar, MD.

About Cytonus Therapeutics Inc.

Cytonus Therapeutics Inc. is a San Diego based biotech company that has developed a vast platform of proprietary immunotherapeutic products to treat a wide range of medical conditions including cancers, infectious diseases, inflammatory diseases and cognitive disorders, and to improve patient outcomes. Its proprietary Cargocyte™ technologies are next-generation biomolecular delivery devices which have numerous medical applications across unmet therapeutic areas. Cargocytes™ are engineered to safely transport a multiplicity of therapeutic payloads into difficult-to-reach targeted tissues, and can be programmed to deliver selective, potent, and controllable “off-the-shelf” therapies. Cytonus’ vast platform of therapeutics and vaccines has the potential to improve the health and lives of people with life-threatening conditions. For more information, we invite you to visit the Cytonus website at https://Cytonus.com. Please follow us on Cytonus on LinkedIn and on Twitter at: @CytonusTx.

Statements in this news release other than strictly historical facts, such as statements about Cytonus’ plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words “believe,” “expect,” “aim,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. The company undertakes no obligation to publicly update or revise any forward-looking statement. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.

Join Cytonus on LinkedIn and follow its Twitter account at: @CytonusTx

Share article on social media or email:

Kabbage Launches Kabbage Insights™, Allowing Small Businesses To Take Control of Their Cash Flow With Just a Few Clicks


News Image

Kabbage is pleased to launch Insights, taking on this burden for small business owners and providing them with cash flow analyses that large enterprises have at their fingertips. We will continue to level the playing field for the small business owner.

Kabbage, Inc. today launched Kabbage Insights, a fully automated tool that calculates and predicts cash-flow patterns to help small businesses identify cash surpluses and deficits. With the launch, Kabbage addresses one of the most vexing problems faced by small business owners. The new product comes just one month after the public launch of Kabbage Payments™, continuing the company’s rapid innovation to build a suite of integrated products that simplify cash-flow management for U.S. small businesses.

In less than 10 minutes, any small business can connect their real-time financial data to Kabbage Insights and access an analysis of their company’s historical, current and future cash-flow 24/7. The product continually evaluates the transaction activity of a customer over a 90-day period and organizes it in an easy-to-understand dashboard, allowing customers to quickly visualize their net growth without taking the time to calculate it themselves. Kabbage’s customer base of over 220,000 small businesses has immediate access.

As a leader in predictive analytics and artificial intelligence for small businesses, Kabbage Insights produces personalized forecasts to predict the future cash position of a business. Customers can then set a desired low-balance threshold and receive automated alerts if accounts are predicted to dip below it, empowering small businesses to identify, act upon and prevent cash deficits before they occur.

Paired with the Kabbage Small Business Revenue Index, Kabbage Insights is also the first product available that allows small businesses to compare their company’s performance to similarly-sized businesses operating in their state and industry. The result is an unparalleled cash-flow tool that’s free for small businesses, helping them to anticipate changes, benchmark their growth, plan ahead and make more confident business decisions like when to cut expenses, invest or borrow.

With Kabbage Insights, small businesses can:

  • Review cash-flow on the go via the intuitive mobile dashboard.
  • Analyze daily performance and review money movement at a glance.
  • Borrow strategically with forecast data to inform funding decisions.
  • Save time, as studies show 91 percent of small business owners spend as many as 20 hours per week manually calculating cash flow.

“As a small business owner for many years, I spent many sleepless nights trying to figure out whether I’d have the cash to pay my various expenses, including payroll at the end of the month and it’s been a mission of mine to solve this ubiquitous problem for all small business owners ever since,” said Kabbage CEO Rob Frohwein. “Kabbage is pleased to launch Insights, taking on this burden for small business owners and providing them with cash flow analyses that large enterprises have at their fingertips. We will continue to level the playing field for the small business owner.”

About Kabbage

Kabbage, Inc., headquartered in Atlanta, is a data and technology company providing

small businesses cash flow solutions. Its suite of products includes Kabbage Payments, helping small businesses get paid and access the money they earn faster, Kabbage Funding, providing access to flexible lines of credit in minutes, and Kabbage Insights, a powerful and predictive tool to calculate cash flow. To date, Kabbage has provided more than 220,000 U.S. small businesses access to over $9 billion of working capital. Kabbage is funded and backed by leading investors, including the SoftBank Vision Fund, BlueRun Ventures, WildCast Venture Partners, Thomvest Ventures and others. All Kabbage U.S.-based loans are issued by Celtic Bank, a Utah-Chartered Industrial Bank, Member FDIC. Kabbage Payments, LLC, a subsidiary of Kabbage, Inc., is a registered Payment Service Provider/Payment Facilitator sponsored by Fifth ThirdBank, N.A., Cincinnati, OH. For more information, please visit http://www.kabbage.com.

Share article on social media or email:

Crutchfield Dermatology Celebrates 2,000 Verified Positive Patient Reviews!


Charles E. Crutchfield III, M.D.

“I will never rush a patient who may face an unfavorable diagnosis. If I have to choose between compassion and keeping our schedule to the minute, we are going to run late.” – Charles E. Crutchfield III, M.D.

Whether replacing a furnace, installing new carpeting, or finding the best hotel for the next trip, chances are most people read online reviews to help make those selections. Online reviews are increasingly used to help find the best doctor, too. Studies show people benefit from learning about other people’s experiences.

“That’s why we are so proud Crutchfield Dermatology has received so many positive patient reviews,” says Charles E. Crutchfield III, MD, Medical Director of Crutchfield Dermatology. “Having over 2,000 people take the time to recount their positive experience at our clinic is one of the greatest honors we could receive.”

Dr. Crutchfield explains that, like any business, the clinic is “far from perfect.” But it’s the commitment to actively working on getting better every day that sets the clinic apart.

“When a review touches on an experience that is ‘less than ideal’ it gives us a chance to improve,” Crutchfield explains.

The emergence of online reviews as a prominent information source for consumers comes with challenges. Online reviews for physicians and other professional industries have an inherent selection bias.

For example, many negative reviews will express dissatisfaction that a medical condition isn’t cured when it’s well-known there is no cure for the disease. In those cases, which are not the fault or responsibility of the physician, there is no way to satisfy the patient.

Likewise, businesses can take the blame for third-party actors. For instance, a patient may feel a medicine costs too much or be upset that their insurance does not cover it. Even though this is beyond the control of the doctor, the patient will attribute the problem to that clinic rather than the health plan denying payment or pharmaceutical company charging the high price.

With over 2,000 verified, positive reviews about the quality of Crutchfield Dermatology’s services, are there any concerns expressed by patients about the clinic?

“Yes, of course,” responds Clinic Manager, Tim Quesnell. “Like all clinics, patients don’t like to wait.”

Whether it stems from sensitivity to the value of time in an increasingly fast-paced world, or some other cause, medical clinics and other service businesses struggle to maximize access to their services while minimizing wait times.

“We work every day to improve the schedule,” Quesnell says. “But medicine is not like the restaurant business. Things come up every clinic, and sometimes patients need extra attention.”

Crutchfield adds, “I will never rush a patient who may face an unfavorable diagnosis. If I have to choose between compassion and keeping our schedule to the minute, we are going to run late. Most people who have to wait when those conditions arise realize that if they were ever in need of a little extra attention, we would give it to them, too.”

But not all people look at commercial experiences with that level of empathy, which is why the 2K mark for positive reviews is so remarkable.

“Most people who have a great result or outcome go on with normal life. They go shopping with friends, run errands, and do other routine things that don’t include writing a review,” explains Darrin Rosha, a Minnesota attorney who works with clients on reputation issues. “People don’t usually run to their computer to express how happy they are. Rather, the desire to vent about a negative experience is far more powerful.”

Because so many patients have positively reviewed Crutchfield Dermatology, a remarkable occurrence in its own right, those reviews and word of mouth among professionals have resulted in over a thousand physicians sending patients Crutchfield Dermatology for dermatologic expertise and care. Although reviews and referrals reflect how Crutchfield Dermatology is a center of excellence and in high demand, there are aspects of the clinic that reviews don’t show.

For instance, many dermatology clinics pass more and more of their patient contact and care to mid-level personnel. Dr. Crutchfield has refused to hire physician assistants or other midlevel providers: He insists on seeing, diagnosing, and treating his patients personally. This commitment to patient care has resulted in the premium care Dr. Crutchfield is known for and fiercely proud of.

“We know we are in demand, and that leads to access challenges. We tell patients if they have a time-sensitive schedule that will not allow them to wait if necessary, we are probably not the right practice for them, Crutchfield continues.

Quesnell adds, “But if a patient demands the highest quality care and the knowledge that they will be seen by a professor of dermatology and one of the best board-certified dermatologists in the country, Crutchfield Dermatology welcomes them with open arms.”

It’s easy to see why Crutchfield Dermatology is so proud to have received over 2,000 verified, authentic positive patient reviews located at http://www.CrutchfieldDermatologyReviews.com

About Charles E. Crutchfield III, M.D.:

Charles E. Crutchfield III, M.D. is a graduate of the Mayo Clinic Medical School and a Clinical Professor of Dermatology at the University of Minnesota Medical School. He currently is the Medical Director of Crutchfield Dermatology in Eagan, (serving the greater Minneapolis-St. Paul area), Minnesota. Dr. Crutchfield is an annual selection of the “Top Doctors” issue of Mpls. St. Paul magazine. He is the only dermatologist to have been selected as a “Best Doctor for Women” by Minnesota Monthly magazine since the inception of the survey. Dr. Crutchfield has been selected as one of the “Best Doctors in America,” an honor awarded to only 4% of all practicing physicians. Dr. Crutchfield is the co-author of a children’s book on sun protection and dermatology textbook. He is a member of the AΩA National Medical Honor Society, an expert consultant for WebMD and CNN, and a recipient of the Karis Humanitarian Award from the Mayo Clinic School of Medicine. Dr. Crutchfield was also given “first a physician” award, Healthcare Hero, 100 most influential healthcare leaders in Minnesota, and one of the Top 100 African –American Newsmakers in the United States by TheGrio, an affiliate of NBC News. https://en.wikipedia.org/wiki/Grio_Awards

Vantage Consulting Group Paves Way for Drug Manufacturers to Implement and Demonstrate GS1 EPCIS 1.2 Compliance for FDA’s DSCSA Track and Trace Requirements


Drummond is pleased to announce that QU4RTET 3.0 has earned Drummond’s EPCIS 1.2 Certification seal. Vantage can now engage with their clients for implementation of QU4RTET so that these manufacturers can then earn their GS1 EPCIS 1.2 Trustmark’s for the Manufacturer Test Scenarios.

Drummond Group, the trusted leader in software compliance and interoperability testing, announced Vantage Consulting Group selected Drummond for the validation and certification of the Level-4 open source solution QU4RTET 3.0 in accordance to GS1 US Rx EPCIS Conformance Testing Program.

Drummond is pleased to announce that QU4RTET 3.0 has earned Drummond’s EPCIS 1.2 Certification seal. Vantage can now engage with their clients for implementation of QU4RTET so that these manufacturers can then earn their GS1 EPCIS 1.2 Trustmark’s for the Manufacturer Test Scenarios.

With GS1 US overseeing the program, Drummond validated QU4RTET’s compliance to all seven manufacturer role-based test scenarios as defined by GS1 EPCIS 1.2 Implementation Guidelines.

Vantage is taking a leadership role in ensuring EPCIS 1.2 messages between the manufacturer and the wholesaler are following the proper format and structure to support DSCSA track and trace requirements. Vantage recognizes the following advantages in bringing QU4RTET into compliance, the first L4 Software Solution to be validated and certified by Drummond for EPCIS 1.2.

  • It is essential to demonstrate compliance to the FDA’s Drug Supply Chain Security Act (DSCSA) for traceability in the supply chain
  • Earning the Drummond EPCIS 1.2 Certification seal is the first step in demonstrating compliance to DSCSA interoperability requirements for serialization. It is very important to us as a QU4RTET integration provider to ensure our customers can implement a GS1 EPCIS 1.2 certified solution so that they can earn their GS1 Trustmark for their implementation of QU4RTET 3.0

“Drummond’s rigorous yet intuitive EPCIS Conformance Portal, a web-based compliance testing service, was key to providing us with a straightforward way to demonstrate QU4RTET compliance to GS1 EPCIS 1.2 Implementation Guidelines. This provides assurance to our customers that Vantage is committed to guiding pharmaceutical manufacturers toward meeting DSCSA track and trace requirements” said George Poltorak, Vantage Consulting Group CEO.

“Drummond was the first testing service to be certified by GS1 and we are pleased to announce QU4RTET 3.0 has been conformance validated against GS1 EPCIS 1.2 Implementation Guidelines, which define how GS1 standards can be used to meet DSCSA track and trace requirements in an interoperable way” said Aaron Gomez, Drummond, Principal, Supply Chain Security business unit.

Further, Drummond is committed to the GS1 EPCIS Conformance Program and we welcome any stakeholder in the pharmaceutical supply chain impacted by FDA’s DSCSA mandate to contact Drummond to learn more about this testing service and for inquires to discuss how to gain trial access and a request demonstration.

————————————————————————

About Drummond

Drummond offers a comprehensive suite of services (including GS1 GDSN Data Pool Certification Testing), to help you achieve compliance with regulatory information security mandates and ensure critical business applications meet interoperability and application conformance. Increase trust, gain expertise and experience our proven methodologies and attention to detail as we partner with you for your long-term success. For more information visit: drummondgroup.com

About Vantage Consulting Group

Vantage is the manufacturing productivity company. For manufacturers facing safety, quality, or efficiency challenges, we provide strategic guidance and cost-effective execution of initiatives to improve serialization, packaging, inspection and more. Our team is seasoned, lean, on time and within your budget. vantage-cg.com.

About QU4RTET

QU4RTET is a collaborative track and trace software and an open-source platform. The code is perpetually open source once released and, thus, public domain.

QU4RTET proudly boasts historic support by capital investors and is bolstered by developer time and resources. The open-source code has been collectively created by experienced developers with decades of industry knowledge. QU4RTET supports EPCIS 1.2. qu4rtet.com/about/

Share article on social media or email: